Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Experimental eye drops for GVHD dry eye show early promise but trial stops short

NCT ID NCT06495307

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a new eye drop (rhPRG4) in 3 adults with moderate to severe dry eye from chronic graft-versus-host disease (GVHD), a complication of bone marrow transplants. The goal was to see if the drops safely improve dryness and eye surface damage. The trial was terminated early, so results are limited.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1/2

Runs two stages together: safety and dose first, then whether the treatment works.

Participants

3 people

The number who actually took part.

Started

Feb 2025

Finished

Mar 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 90 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Diagnosis and Main Criteria for Inclusion: All to be queried and checked at the screening visit (V1): 1. Subjects 18 years of age or older; 2. Subjects diagnosed with oGVHD for at least 3 months (current use of artificial tears for the treatment of GVHD); 3. VAS Eye Dryness (100-point scale) score ≥ 60 mm; 4. Tear Osmolarity ≥ 312 in either eye; 5. Corneal staining score with fluorescein ≥ 2 using the Oxford scale in the worst performing eye; staining must include quadrants beyond only inferior or superior staining; 6. Only subjects who satisfy all Informed Consent requirements may be included in the study. Exclusion Criteria: Diagnosis and Main Criteria for Exclusion: 1. Evidence of an active ocular infection in either eye; 2. History or presence of ocular surface disorders not related to oGVHD in either eye, including but not limited to significant conjunctivochalasis, superior limbic keratoconjunctivitis, limbal stem cell deficiency, allergic conjunctivitis, giant papillary conjunctivitis, atopic keratoconjunctivitis, anterior basement membrane dystrophies, neurotrophic keratitis, corneal dystrophy, exposure keratitis and moderate to severe blepharitis; 3. History of any ocular surgery (including laser or refractive surgical procedures) in either eye within 90 days before study enrollment. Ocular surgery will not be allowed during the study treatment period and elective ocular surgery procedures should not be planned during the duration of the follow-up period; 4. Initiation of new therapeutic modalities within 30 days of recruitment; 5. Artificial rescue tears are allowed as long as they are recorded in a diary; 6. Known hypersensitivity to one of the components of the study or procedural medications; 7. Participation in another clinical study at the same time as the present study or within 60 days of screening/baseline visit; 8. History of drug, medication or alcohol abuse or addiction; 9. Females of childbearing potential (those who are not surgically sterilized or post-menopausal for at least 1 year) are excluded from participation in the study if they meet any one of the following conditions: 1. are currently pregnant or, 2. have a positive result on the urine pregnancy test at the Screening/Baseline Visit or, 3. intend to become pregnant during the entire course of and 30 days after the study treatment periods, or, 4. are breast-feeding or, 5. not willing to use highly effective birth control measures, such as: Hormonal contraceptives - oral, implanted, transdermal, or injected and/or mechanical barrier methods, during the entire course of and 30 days after the study treatment periods.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Ocular graft versus host disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • OTA

    Brisbane, Queensland, Australia

  • Sydney Eye Hospital

    Sydney, New South Wales, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.